Clinical study on simultaneous resection of liver metastases combined with hyperthermic intraperitoneal chemotherapy for synchronous colorectal cancer liver metastasis
Wenxiao Li,Hui Ren,Hongchao Mou,Jie Li,Lijun Dong,Guangjin Li,Mingxuan Xing
DOI: https://doi.org/10.1016/j.gassur.2024.01.039
2024-02-01
Journal of Gastrointestinal Surgery
Abstract:Objective This study aimed to analyze the clinical effect of simultaneous resection of liver metastases combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on synchronous colorectal cancer liver metastasis. Methods 144 patients with synchronous colorectal cancer liver metastasis who were admitted to our hospital from January 2018 to January 2019 were randomly assigned into a control group and an intervention group. The patients in the control group received simultaneous resection of liver metastases. The patients in the intervention group obtained simultaneous resection of liver metastases combined with HIPEC. The recent total effective rate of the two groups was compared, and the disease control rate of the two groups was calculated at 3 months after treatment. The patients were followed up for 3 years. The survival time of the two groups was observed and compared. Fasting venous blood was collected from patients in the two groups, and the carcinoembryonic antigen (CEA) level was compared. The level of quality of life scale (SF-36) and the occurrence of adverse reactions were compared between the two groups. Results The R0 complete resection rate in the intervention group was significantly higher than that in the control group (P < 0.05). The recent total effective rate in the intervention group (87.50%) was significantly higher than that in the control group (59.72%) (P < 0.05). The negative change of CEA in the intervention group was 72.22%, which was prominently higher than that in the control group of 43.06% (χ 2 =12.542, P<0.001). Following a 36-month follow-up, the overall survival rate of the observation group was significantly higher than that of the control group [HR=2.54(1.05~5.48), P<0.001]. The patients in the intervention group had significantly higher life quality scores of health status, social function, emotional function, physical function, and mental health than the control group (P < 0.05). There was no significant difference in the incidence of complications between the two groups (P > 0.05). Age > 60 years, preoperative comorbidities, moderate and high differentiation of tumors, intraoperative blood loss > 150ml and less experienced surgeons were risk factors affecting the occurrence of complications after treatment, and were closely correlated with the prognosis and survival of patients (P < 0.05). Patients with age ≤ 60 years, no preoperative comorbidities, low tumor differentiation, intraoperative blood loss ≤ 150ml, more experienced surgeons and complete R0 resection had a longer survival time. Age > 60 years, preoperative comorbidities, moderate and high differentiation of tumors, intraoperative blood loss > 150ml and less experienced surgeons were independent risk factors affecting the prognosis of patients with colorectal cancer liver metastases (P < 0.05), while R0 surgery was an independent protective factor for the prognosis (P < 0.05). Conclusion In the treatment of synchronous colorectal cancer liver metastases, simultaneous resection of liver metastases in conjunction with HIPEC demonstrated superior efficacy. This approach may potentially extend patient survival and enhance quality of life, and deserve to be extensively used in clinical practice.
gastroenterology & hepatology,surgery